#AANAM – AP-101 Raises No Safety, Tolerability Concerns in Phase 1 Trial

#AANAM – AP-101 Raises No Safety, Tolerability Concerns in Phase 1 Trial

292444

#AANAM – AP-101 Raises No Safety, Tolerability Concerns in Phase 1 Trial

Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. In a Phase 1 trial for amyotrophic lateral sclerosis (ALS), the investigational therapy AP-101 — designed to ease motor symptoms and increase survival in people with the neurodegenerative disease — was found to be safe and well-tolerated at all tested doses. The most commonly reported adverse events, or side…

You must be logged in to read/download the full post.